# Nuclide record rituximab (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/rituximab/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "rituximab" ;
  schema:name "Rituximab"@en ;
  schema:alternateName "Rituximab and Hyaluronidase Human"@en, "Rituxan Hycela"@en, "Rituxan / MabThera (and biosimilars)" ;
  schema:description "Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere."@en ;
  schema:url <https://nuclide.cc/drugs/rituximab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Rituximab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q412323> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Rituximab> ;
  nuclide:status "approved" ;
  nuclide:modality "Monoclonal antibody (anti-CD20, chimeric)" ;
  nuclide:approval "US 1997: Relapsed follicular lymphoma; first antibody approved for cancer", "US 2010: CLL with fludarabine and cyclophosphamide" ;
  nuclide:indications <https://nuclide.cc/indications/dlbcl/> ;
  nuclide:targets <https://nuclide.cc/targets/cd20/> .